Articles from Recludix Pharma, Inc.

--Efficacy comparable to anti-IL4/IL13 antibody control

-- Bruton’s tyrosine kinase (BTK) SH2 inhibitor reduced skin inflammation in a clinically-relevant model of chronic spontaneous urticaria (CSU)-- BTK inhibition through the SH2 domain results in greater selectivity as compared to BTK tyrosine kinase inhibitors (TKIs) or degraders

SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for inflammatory disease, today announced that Nancy Whiting, Pharm.D., its president and chief executive officer, and Ajay Nirula, M.D., Ph.D., its executive vice president and head of research and development, will present an overview of the company at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025 at 11:20 a.m. Eastern Time.

SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for inflammatory disease, today announced that Nancy Whiting, Pharm.D., president and chief executive officer of Recludix, will present an overview of the company’s progress and anticipated milestones for 2025 at the Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The company’s presentation will be on Wednesday, January 15, 2025 at 2:00 p.m. Pacific Time.

SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in discovery of inhibitors of challenging targets for inflammatory disease, today announced that members of Recludix’s management will participate in two investor conferences in December.

-REX-7117 is an oral, potent and selective STAT3 SH2 domain inhibitor, which demonstrated strong efficacy in an in vivo model of inflammatory arthritis

SAN DIEGO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in discovery of inhibitors of challenging targets for inflammatory disease and cancer, today announced that Fierce Biotech has named it as one of 2024’s “Fierce 15” biotechnology companies. The annual special report features the most innovative and promising biotechnology companies in the industry.

-- In a preclinical model of psoriasis, the efficacy of oral small molecule REX-7117 was comparable to an anti-IL-17A biologic

Newly appointed head of R&D, Dr. Nirula, joins Recludix from Eli Lilly with over two decades of clinical development experience

SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging targets for inflammatory disease and cancer, today announced that members of Recludix’s management will host meetings at two investor conferences in March.

SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging targets for inflammatory disease and cancer, today announced that Nancy Whiting, Pharm.D., chief executive officer of Recludix, will present at two investor conferences in February.

SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging targets for inflammatory disease and cancer, today announced that Nancy Whiting, Pharm.D., chief executive officer of Recludix, will present at two investor conferences in November.

- REX-7117 found to have superior efficacy to a clinically-relevant dose of deucravacitinib in a preclinical model of psoriasis

- Pioneering compounds believed to be the first orally administered reversible inhibitors to bind to and inhibit the SH2 domain potently and selectively

SAN DIEGO, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging targets for inflammatory disease and cancer, today announced that Nancy Whiting, Pharm.D., chief executive officer of Recludix, will present at multiple investor conferences in September.

- Recludix to receive $125 million in near-term payments and potentially more than $1.2 billion subject to future milestones, and up to double-digit royalties on sales -

SAN DIEGO, March 07, 2023 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced that Nancy Whiting, Pharm.D., chief executive officer of Recludix, will present an overview of the company at the virtual Oppenheimer 33rd Annual Healthcare Conference. The company’s presentation will be on Tuesday, March 14, 2023 at 12:40 p.m. Eastern Time.

SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced that Nancy Whiting, Pharm.D., chief executive officer of Recludix, will present an overview of the company at the Guggenheim Healthcare Talks Oncology Conference in New York, NY. The company’s presentation will be on Wednesday, February 8, 2023 at 2:45 p.m. Eastern Time.

SAN DIEGO, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced that Nancy Whiting, Pharm.D., chief executive officer of Recludix, will present an overview of the company at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The company’s presentation will be on Thursday, January 12, 2023 at 10:00 a.m. Pacific Time.

SAN DIEGO, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced the appointment of Paul A. Smith, Ph.D., as senior vice president of biology.

SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced the appointment of Matthew Caldemeyer as chief business officer.